Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of algorithmic testing and physician oversight, announced that it closed on its seed round of $1.2 million led by Avestria Ventures, with participation from Joyance Partners, both early-stage funds focused on improving health. The company also named Rajni Natesan, MD, MBA as its Chief Executive Officer.
Dr. Natesan is an experienced executive and medical doctor with an extensive background scaling startups at the intersection of healthcare and technology, with a focus on artificial intelligence and machine learning. ‘Clarified Precision Medicine is offering the right technology at the right time,’ Dr. Natesan said. ‘I’m excited to guide Clarified through this period of commercialization and growth as we follow through on our mission to provide any patient, anywhere, with cutting-edge, guidelines-based access to precision medicine.’
Founded in 2021 by Dr. Lincoln Nadauld, MD, PhD, Lisa Alderson, MBA, Howard McLeod, PharmD, and Jody Simon, PharmD, Clarified Precision Medicine uses an algorithm to analyze NGS lab results and then works with oncologists to interpret genomic test results to recommend the best targeted treatment. ‘Dr. Natesan is the perfect leader to help us scale Clarified Precision Medicine to ensure that oncology practices across the country have access to expert guidance to deliver improved outcomes,’ said Clarified Precision Medicine Co-founder Lisa Alderson.
Clarified Precision Medicine is already supporting numerous U.S. oncology practices and testing labs and offers flexible payment options, including direct insurance billing in some cases. More information on Clarified Precision Medicine solutions is available from the Clarified Precision Medicine Business Development team.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Clarified Precision Medicine Raises $1.2 Million, Appoints New CEO.